AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
263.46B
Market cap263.46B
Price-Earnings ratio
25.26
Price-Earnings ratio25.26
Dividend yield
1.86%
Dividend yield1.86%
Average volume
3.24M
Average volume3.24M
High today
$170.06
High today$170.06
Low today
$169.63
Low today$169.63
Open price
$168.14
Open price$168.14
Volume
9.39K
Volume9.39K
52 Week high
$212.71
52 Week high$212.71
52 Week low
$137.23
52 Week low$137.23

Stock Snapshot

The current AstraZeneca(AZN) stock price is $169.64, with a market capitalization of 263.46B. The stock trades at a price-to-earnings (P/E) ratio of 25.26 and offers a dividend yield of 1.86%.

As of 2026-07-20, AstraZeneca(AZN) stock has fluctuated between $169.63 and $170.06. The current price stands at $169.64, placing the stock +0.0% above today's low and -0.2% off the high.

The AstraZeneca(AZN)'s current trading volume is 9.39K, compared to an average daily volume of 3.24M.

During the past year, AstraZeneca(AZN) stock moved between $137.23 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $137.23 at its lowest and $212.71 at its peak.

AZN News

Simply Wall St 3h
AstraZeneca Stock And Two UK Value Shares Trading Below Cash Flow Estimates - simplywall.st

...

AstraZeneca Stock And Two UK Value Shares Trading Below Cash Flow Estimates - simplywall.st
The Motley Fool 2d
Cathie Wood Just Bet Big on This Biotech Stock

Cathie Wood's ARK Genomic Revolution ETF (ARKG 0.55%) focuses on companies in the genomics sector, especially in healthcare. Since the beginning of July, Wood h...

Cathie Wood Just Bet Big on This Biotech Stock
TipRanks 3d
AstraZeneca’s New Saruparib Trial Targets Next Wave of Prostate Cancer Growth

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an...

Analyst ratings

80%

of 30 ratings
Buy
80%
Hold
13.3%
Sell
6.7%

More AZN News

TipRanks 3d
AstraZeneca Backs New EGFR Lung Cancer Combo In Fresh Phase 2 Trial

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an...

TipRanks 5d
AstraZeneca Completes Key Pediatric Asthma Inhaler Study, Setting Up Next Moves for Symbicort

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an...

TipRanks 6d
AstraZeneca’s Elecoglipron Takes On Semaglutide in Key Phase III Diabetes Trial

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an...

TipRanks 6d
AstraZeneca Advances AZD7760 Trial in Japan, Quietly Expanding Its Infection-Prevention Pipeline

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an...

TipRanks 6d
AstraZeneca Deepens NSCLC Precision Strategy With New MET Gene Profiling Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an...

TipRanks 6d
AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M

Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca (AZN) for Zegfrovy, an oral irreversible epidermal growth factor...

The Wall Street Journal 6d
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

AstraZeneca will pay $600 million initially, and make additional payments of up to $900 million upon reaching goals. Paul Ellis / Agence France-Presse / Getty I...

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.